Cases & Deals

  • Home
  • Practices
  • Al Hammadi Company for Development and Investment acquires 35% of Sudair Pharmaceuticals

Share

Al Hammadi Company for Development and Investment acquires 35% of Sudair Pharmaceuticals

November 2021

Client(s) Al Hammadi Company for Development and Investment

Jones Day advised Al Hammadi Company for Development and Investment in the $31.5 million acquisition of a 35% interest in Sudair Pharmaceutical Company.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.